Sensei Biotherapeutics (NASDAQ:FTH) Releases Quarterly Earnings Results, Misses Expectations By $0.13 EPS

Sensei Biotherapeutics (NASDAQ:FTH) posted its quarterly earnings results on Tuesday. The company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.13), Zacks reports.

Sensei Biotherapeutics Stock Performance

FTH stock traded down $0.28 during midday trading on Thursday, hitting $19.70. 113,678 shares of the company’s stock were exchanged, compared to its average volume of 251,891. Sensei Biotherapeutics has a one year low of $7.45 and a one year high of $42.14. The company has a market cap of $509.18 million, a P/E ratio of -0.14 and a beta of -0.15. The stock’s fifty day moving average is $27.95.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Raymond James Financial started coverage on shares of Sensei Biotherapeutics in a report on Friday, July 31st. They set an “outperform” rating and a $56.00 target price for the company. Needham & Company LLC initiated coverage on Sensei Biotherapeutics in a research note on Friday, August 21st. They issued a “buy” rating and a $56.00 price target on the stock. Wall Street Zen lowered Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, September 26th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price objective on shares of Sensei Biotherapeutics in a research note on Tuesday, August 11th. Finally, William Blair assumed coverage on Sensei Biotherapeutics in a report on Friday, October 16th. They issued an “outperform” rating for the company. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $56.17.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is designed to activate and direct the immune system against tumors, with an emphasis on treatments that may address immune-suppressive mechanisms in the tumor microenvironment.

Sensei’s pipeline has included SNS-101, an investigational antibody targeting VISTA, an immune checkpoint believed to limit anti-tumor immune responses, and SNS-301, an investigational cancer vaccine developed using the company’s ImmunoPhage platform.